Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07286058 · ClinicalTrials.gov registry record · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
A Phase 3 study of Psoriatic Arthritis, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,182
- Enrollment target
- 1
- Study location
NCT07286058 is a Phase 3 study of Psoriatic Arthritis that is actively recruiting participants, run by Takeda. The registered enrollment target is 1,182 participants, above the 828-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07286058, a Phase 3 study of Psoriatic Arthritis, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,182 participants
- Enrollment target
- 1
- Study location
Study Summary
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD). Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.
Conditions Studied
Interventions
- DRUG Zasocitinib
Study Locations (1)
California
- First OC Dermatology Research Inc. - Fountain Valley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,182 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2029-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07286058
The ClinicalTrials.gov registry entry for NCT07286058 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,182 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 828-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (43% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Zasocitinib is the first listed.
NCT07286058 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07286058 about?
NCT07286058 is a clinical study titled "Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis". Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) t...
What is the current status of trial NCT07286058?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,182 participants. The study started on 2026-03-11. Estimated completion is 2029-12-18.
What conditions does trial NCT07286058 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT07286058?
The interventions under investigation include: Zasocitinib (DRUG).
Who is sponsoring clinical trial NCT07286058?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07286058 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.